92 filings
Page 3 of 5
8-K
meu4ikz
2 May 19
Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
4:05pm
8-K
obyq4rh3h w8g2lc9ga
13 Mar 19
Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
4:12pm
8-K
yuk4tx7t1ulzko3x 5mf
7 Nov 18
Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
12:00am
8-K
cglj vbjt8qyj
21 Sep 18
Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock
6:05am
8-K
00cfewj
18 Sep 18
Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in LDL-C in Patients Receiving VK2809
12:00am
8-K
vxs3v ite22e
9 Aug 18
Viking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
12:00am
8-K
p738btgt7nvf3wi
12 Jun 18
Viking Therapeutics Announces Closing of Public Offering of Common Stock
7:10am
8-K
6iodu8 iv2a4
7 Jun 18
Viking Therapeutics Announces Pricing of $67.5 Million Public Offering of Common Stock
1:41pm
8-K
esqj gptcx
31 May 18
Entry into a Material Definitive Agreement
12:00am
8-K
e2wxy 92v
9 May 18
Viking Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
12:00am
8-K
s8k7ejqey7rr1uk7f7
7 Mar 18
Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
12:00am
8-K
ucgovrj
6 Feb 18
Viking Therapeutics Announces Closing of Public Offering of Common Stock
12:00am
8-K
9kssruasb86vehki92
2 Feb 18
Viking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock
12:00am
8-K
ntloza inj
23 Jan 18
Departure of Directors or Certain Officers
12:00am
8-K
9g0s0s4y qtzc
11 Dec 17
Viking Therapeutics Announces Closing of Public Offering of Common Stock
12:00am
8-K
1boncdei3
7 Dec 17
Viking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock
12:00am
8-K
lg56o6 bov9
28 Nov 17
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
12:00am
8-K
pcb5y9eoc
8 Nov 17
Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
l0qa8h
29 Sep 17
Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital
12:00am
8-K
g4beb9cca5pxrb0ht9e
9 Aug 17
Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
12:00am